The global stomach cancer treatment market was valued at USD 2.61 billion in 2018 and is expected to grow at a CAGR of 16.0%, reaching USD 20.92 billion by 2032. In 2018, the Asia Pacific region led the market, accounting for a 38.7% share.

Stomach cancer is the fifth most prevalent cancer globally, with 6,697 new cases of gastric carcinoma diagnosed annually, according to Cancer Research U.K. This cancer is classified into three main types, with Gastric Adenocarcinoma being the most common, accounting for 90%-95% of all cases. The rarer types include Gastrointestinal Stromal Tumors (GIST) and Gastric Neuroendocrine Tumors (gNET). The increasing incidence of stomach cancer, combined with the limited availability of first-line treatment options, has driven significant research efforts by pharmaceutical companies to develop new drugs.

This has also led to several significant strategic collaborations between pharmaceutical companies. For instance, in March 2019, AstraZeneca formed a development and commercialization agreement with Daiichi Sankyo, Inc. for trastuzumab deruxtecan, an antibody-drug conjugate under investigation for gastric carcinoma. As a result, the stomach cancer treatment market is gaining significant traction. Additionally, active government support is expected to further drive market growth.

Get a Free Sample Research PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/stomach-gastric-cancer-treatment-market-102094

List Of Key Companies Covered In Stomach Cancer Treatment Market:

·         Ipsen Pharma

·         Merck & Co., Inc.

·         Bristol-Myers Squibb Company

·         Eli Lilly and Company

·         F. Hoffmann-La Roche Ltd

·         Novartis AG

·         Bayer AG

·         Celltrion Inc.s

·         TAIHO PHARMACEUTICAL CO., LTD.

·         Jiangsu Hengrui Medicine Co., Ltd.

Market Drives:

Stomach cancer is becoming a leading cause of death worldwide. According to the WHO, the number of new stomach cancer cases is expected to rise from 1.03 million in 2018 to 1.24 million by 2025. This growing incidence of gastric carcinoma is likely to drive increased demand for stomach cancer treatments during the forecast period, positioning it as a key trend in the market. Additionally, the growing use of advanced diagnostic tools for early detection is expanding the patient population. This trend is expected to further contribute to the growth of the stomach cancer drugs market in the coming years.

Market Segmentation:

The stomach cancer treatment market is segmented by drug type, with PD-1 inhibitors expected to dominate due to increased research and approvals, such as Keytruda’s FDA approval in 2017. The HER2 antagonists segment is projected to grow due to government support for biosimilars and pipeline candidates. VEGFR antagonists are also set to expand, driven by the rising prevalence of stomach cancer. The "others" segment, which includes chemotherapy drugs like Lonsurf, fluorouracil, and capecitabine, remains strong, especially in developing countries. By disease indication, gastric adenocarcinoma is expected to dominate, driven by rising prevalence and the adoption of targeted therapies. The parenteral route of administration is likely to register the highest CAGR, thanks to favorable reimbursement and more intravenous drugs. Hospital pharmacies are anticipated to benefit from government support, while retail and online pharmacies will see growth due to increasing treatment centers and online drug sales.

Regional Analysis:

Asia Pacific, with a revenue of USD 1.01 billion in 2018, holds the largest share of the stomach cancer treatment market, driven by rising gastric cancer cases in Japan, China, and India, and the adoption of PD-1 inhibitors. The region is expected to maintain dominance throughout the forecast period. North America’s market growth is fueled by strategic collaborations, increased R&D spending, and the rising incidence of stomach cancer, with 27,510 cases estimated in the U.S. in 2019. Europe is set to experience growth due to new product launches, favorable health reimbursement, and collaborations like Boehringer Ingelheim's partnership with PureTech Health. In Latin America and the Middle East & Africa, improving healthcare infrastructure and unmet patient needs are expected to drive demand for gastric carcinoma treatments.

Key Industry Developments:

·   In May 2021, Bold Therapeutics received Orphan Drug Designation (ODD) for BOLD-100, a first-in-class ruthenium-based small molecule therapeutic, for the treatment of gastric cancer.

·  In April 2021, Bristol Myers Squibb gained U.S. FDA approval for Opdivo (nivolumab) as the first immunotherapy for the first-line treatment of gastric cancer.